Abdulrahman Arshed N. Alharfy

Role of Anti-VEGF (Bevacizumab) in Management of Neovascular Glaucoma: A Review

Abdulrahman Arshed N. Alharfy, Marwan Saleh D. Albalawi, Abdulmajeed Mousa Alzahrani, Ruby Naif M. Alsubaie, Amani Ahmad S. Albalawi, Waad Ali Alkaabneh, Abdullah Ibrahim Altidlawi, Amal Nafea J. Alharbi, Afnan Mohammed H. Almutairi & Rola Ali S. Alotabi · Journal of Pharmaceutical Research International · 2021

Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized...

Open access Research Article 10.9734/jpri/2021/v33i40A32237

Causes and Management of Hyperkyphosis

Khaled Nasser Almujel, Abdalah Emad Almhmd, Abdulrahman Arshed N. Alharfy, Ibrahim Abdullah Said Albalawi, Tariq Bander F. Alanazi, Aysha Jaber Alshehri, Bedour Eid H. Alatawi, Abdullah Dhafer Alshehri, Meshari Salman Alhawiti & Shumoukh Homoud Alshehri · Journal of Pharmaceutical Research International · 2021

Hyperkyphosis is identified when kyphosis angle exceeds the normal ranges. In overall, hyperkyphosis upsurges with age, particularly after the age of 40. It arises as a consequence of multifactorial causes and is associated with increased health susceptibility. Separately from th...

Open access Research Article 10.9734/jpri/2021/v33i35B31892